A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 6, Issue 6, 2011, Pages 1104-1109

  Han, Baohui ^a   Xiu, Qingyu ^b   Wang, Huimin ^a   Shen, Jie ^a   Gu, Aiqin ^a   Luo, Yi ^c   Bai, Chunxue ^d   Guo, Shuliang ^e   Liu, Wenchao ^f   Zhuang, Zhixiang ^g   Zhang, Yang ^h   Zhao, Yizhuo ^a   Jiang, Liyan ^a   Zhou, Jianying ⁱ   Jin, Xianqiao ^j  

^a SHANGHAI CHEST HOSPITAL   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c HUNAN CANCER HOSPITAL   (China)

^d ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^e THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^f FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^g THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^h DALIAN MEDICAL UNIVERSITY   (China)

ⁱ ZHEJIANG UNIVERSITY   (China)

^j SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

more..

Author keywords

Carboplatin; Endostar; NSCLC; Paclitaxel; Recombinant human endostatin

Indexed keywords

CARBOPLATIN; ENDOSTAR; PACLITAXEL; RECOMBINANT ENDOSTATIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GRANULOCYTOPENIA; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; OBJECTIVE RESPONSE RATE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN DISEASE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 79958178412     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182166b6b     Document Type: Article

References (18)

1. Qin XJ, Shi HZ. Major causes of death during the past 25 years in China. Chin Med J (Engl) 2007;120:2317-2320.
2. Soon YY, Stockler MR, Askie LM, et al. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol 2009;27:3277-3283.
3. Ergun S, Tilki D, Oliveira-Ferrer L, et al. Significance of vascular stabilization for tumor growth and metastasis. Cancer Lett 2006;238: 180-187. (Pubitemid 43867907)
4. Folkman J. Endogenous inhibitors of angiogenesis. Harvey Lect 1996; 92:65-82.
5. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285. (Pubitemid 28015876)
6. Zhuang HQ, Yuan ZY. Process in the mechanisms of endostatin combined with radiotherapy. Cancer Lett 2009;282:9-13.
7. Folkman J. Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action. Exp Cell Res 2006;312:594-607. (Pubitemid 43290336)
8. Grosios K. Endostatin (EntreMed). IDrugs 2000;3:799-810.
9. Wang J, Sun Y, Liu Y. Results of randomised, multicentre, double-blind phase III trial of rh-endostantin (YH-16) in treatment of advanced non-small cell lung cancer patients. Chin J Lung Cancer 2005;8:283-290. (Pubitemid 41206392)
10. Therasse P, Arbuck SG. New guidelines to evaluate the response to treatment in solid tumors. Breast Cancer 2005;12.
11. Bolard P, Quantin C, Esteve J, et al. Modelling time-dependent hazard ratios in relative survival: application to colon cancer. J Clin Epidemiol 2001;54:986-996. (Pubitemid 32888365)
12. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98. (Pubitemid 34438899)
13. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 2542-2550. (Pubitemid 44917502)
14. Martin R, Joachim P, Petr Z, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009; 8:1227-1234.
15. Yang L, Wang JW, Sun Y, et al. Randomized phase II trial on escalated doses of Rh-endostatin (YH-16) for advanced non-small cell lung cancer. Chin J Oncology 2006;28:138-141.
16. Zhong H, Han B, Tourkova IL, et al. Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth. Clin Cancer Res 2007;13:5455-5462. (Pubitemid 47510373)
17. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-1886. (Pubitemid 30207647)
18. Gutierrez M, Giaccone G. Antiangiogenic therapy in nonsmall cell lung cancer. Curr Opin Oncol 2008;20:176-182. (Pubitemid 351317405)